Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Amag Pharmaceuticals (AMAG)

Amag Pharmaceuticals (AMAG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 318,076
  • Shares Outstanding, K 33,910
  • Annual Sales, $ 474,000 K
  • Annual Income, $ -65,760 K
  • 60-Month Beta 0.35
  • Price/Sales 0.65
  • Price/Cash Flow 5.74
  • Price/Book 0.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.51
  • Number of Estimates 3
  • High Estimate -0.44
  • Low Estimate -0.61
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +15.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.89 +4.05%
on 11/08/19
13.53 -31.63%
on 10/28/19
-1.80 (-16.25%)
since 10/11/19
3-Month
8.89 +4.05%
on 11/08/19
13.53 -31.63%
on 10/28/19
-1.11 (-10.71%)
since 08/09/19
52-Week
6.81 +35.83%
on 08/07/19
19.44 -52.42%
on 12/04/18
-8.59 (-48.15%)
since 11/09/18

Most Recent Stories

More News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG

Pomerantz LLP is investigating claims on behalf of investors of AMAG Pharmaceuticals, Inc. ("AMAG" or the "Company") (NASDAQ: AMAG). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

AMAG : 9.25 (-1.39%)
AMAG Sees Hammer Chart Pattern: Time to Buy?

AMAG Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

AMAG : 9.25 (-1.39%)
AMAG Q3 Loss Wider Than Expected, Revenues Lag Estimates

AMAG disappoints investors with earnings and sales miss in the third quarter.

AMAG : 9.25 (-1.39%)
ACOR : 2.19 (-6.41%)
ANIK : 60.23 (+0.02%)
BGNE : 191.72 (-3.87%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG

Pomerantz LLP is investigating claims on behalf of investors of AMAG Pharmaceuticals, Inc. ("AMAG" or the "Company") (NASDAQ: AMAG). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

AMAG : 9.25 (-1.39%)
AMAG Pharmaceuticals (AMAG) Reports Q3 Loss, Lags Revenue Estimates

AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -37.25% and -5.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?...

AMAG : 9.25 (-1.39%)
AMAG Pharmaceuticals Announces Third Quarter 2019 Financial Results and Provides Corporate Update

Commercial products achieve strong revenue and market share performance

AMAG : 9.25 (-1.39%)
The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG

The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG

AMAG : 9.25 (-1.39%)
AMGN : 220.70 (-0.19%)
GILD : 64.64 (-1.13%)
ALXN : 109.01 (-1.61%)
Amag Pharmaceuti Set to Possibly Rebound After Yesterday's Selloff of 24.98%

Amag Pharmaceuti (NASDAQ:AMAG) traded in a range yesterday that spanned from a low of $9.26 to a high of $10.24. Yesterday, the shares fell 25.0%, which took the trading range below the 3-day low of...

AMAG : 9.25 (-1.39%)
Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More

Key highlights include earnings updates, collaboration deals, and regulatory and pipeline updates.

SNY : 45.86 (unch)
AMAG : 9.25 (-1.39%)
AMGN : 220.70 (-0.19%)
ALXN : 109.01 (-1.61%)
REGN : 344.28 (+0.73%)
GILD : 64.64 (-1.13%)
AMAG Reports on FDA Advisory Committee Meeting for Makena(R) (Hydroxyprogesterone Caproate Injection)

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the U.S. Food and Drug Administration's (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee met to better understand and interpret the...

AMAG : 9.25 (-1.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade AMAG with:

Business Summary

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the...

See More

Key Turning Points

2nd Resistance Point 9.58
1st Resistance Point 9.42
Last Price 9.25
1st Support Level 9.12
2nd Support Level 8.98

See More

52-Week High 19.44
Fibonacci 61.8% 14.62
Fibonacci 50% 13.13
Fibonacci 38.2% 11.63
Last Price 9.25
52-Week Low 6.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar